Clinical Trial Update: Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion [Phase 2]

View source ↗

Summary

This entry details a Phase 2 expansion study of ruxolitinib for chronic myelomonocytic leukemia, with results posted in October 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelomonocytic Leukemia

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Chronic Myelomonocytic Leukemia, Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-10-17